This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 200% and 1.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
BIIB vs. MYGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
BIIB vs. MYGN: Which Stock Is the Better Value Option?
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Myriad (MYGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myriad Genetics Shares Fall Despite Partnership With jscreen
by Zacks Equity Research
MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.
MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests
by Zacks Equity Research
Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
by Zacks Equity Research
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.
BMRN or MYGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMRN vs. MYGN: Which Stock Is the Better Value Option?
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Continue to Retain MYGN Stock in Your Portfolio?
by Zacks Equity Research
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
by Zacks Equity Research
MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
Should You Hold Hologic (HOLX) Stock in Your Portfolio Now?
by Zacks Equity Research
Hologic's (HOLX) strength in molecular diagnostics and the enriched Breast Health business are encouraging.
Walgreens (WBA) Partners With BARDA to Boost Clinical Research
by Zacks Equity Research
Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.
Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels
by Zacks Equity Research
Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.
Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
by Zacks Equity Research
Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Quest Diagnostics (DGX) be in Your Portfolio Now?
by Zacks Equity Research
Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.
Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised
by Zacks Equity Research
Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.
Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 600% and 2.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 4.03% and 92.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?